AUTONOMOUS DELIVERY ACROSS RWANDA

A decade ago, Rwanda became the first country in the world to launch Zipline’s national autonomous medical delivery service.

Zipline, an artificial intelligence (AI) and robotics company, designs and operates autonomous logistics systems that enable on-demand delivery of blood, vaccines, and essential medicines, fully integrated into national health systems.

In Rwanda, the network supports nationwide coverage and has contributed to improvements in access to healthcare, including a reported 51 percent reduction in maternal deaths.

Now, under a historic expansion agreement between the government and Zipline, Rwanda will also become the first country with full nationwide autonomous logistics coverage.

It will deploy Zipline’s urban delivery system, known as Platform 2 (P2), starting in the capital, Kigali, where a large share of the country’s healthcare demand is concentrated.

“In addition, Rwanda will host Africa’s first AI and robotics testing and research centre, strengthening its position as a leader in advanced technology and innovation on the continent,” acclaims Pierre Kayitana, Country Director of Zipline Rwanda.

“The expansion also includes the construction of a third long-range distribution hub in Karongi, complementing existing hubs in Muhanga and Kayonza.”

The network will support approximately 350 local jobs and further integrate delivery data into Rwanda’s national health information and emergency response systems.

Importantly, the model reflects a strong government-led approach. The US government is providing upfront infrastructure funding, whilst the Rwanda government is committed to financing ongoing operations.

“This ensures the system is financially sustainable, nationally operated, and embedded within Rwanda’s broader strategy for resilient, technology-driven healthcare,” Kayitana affirms.

ADVANCED LOGISTICS LEADER

By scaling what began as an innovative pilot into permanent national infrastructure, Rwanda has cemented its position as a global leader in advanced logistics.

What started as a targeted effort to improve access to blood in a handful of hospitals has evolved into a nationwide autonomous delivery network embedded in the public health system.

“Today, Zipline is responsible for delivering approximately 75 percent of Rwanda’s national blood supply outside of Kigali,” highlights Kayitana.

This next phase goes further; by hosting Zipline’s first overseas R&D hub, Rwanda is positioning itself not only as a user of frontier technology, but as a place where the next generation of AI, robotics, and autonomous logistics systems will be developed. In doing so, the country is helping shape the future of global supply chains.

A decade of operational data shows the tangible impact of this approach, as Zipline’s system has reduced medical waste by enabling centralised inventory and on-demand delivery.

It has also dramatically improved emergency response times for time-critical treatments such as blood for maternal haemorrhages.

This demonstrates that high-tech logistics can be both effective and economically efficient when deployed at national scale.

“Independent studies consistently find that Zipline’s network ranks amongst the highest-impact and most cost-effective health system interventions studied in recent years – improving outcomes across immunisation, maternal health, nutrition programmes, and emergency care whilst strengthening the reliability of national supply chains,” Kayitana highlights.

AUTONOMOUS DELIVERY SYSTEM

Zipline’s next-generation autonomous delivery system, P2, is designed for fast, quiet, and highly precise deliveries in dense urban environments.

Unlike earlier systems built primarily for long-range medical deliveries, P2 is designed to operate within cities, enabling items to be delivered directly to homes, hospitals, offices, and public spaces with very high accuracy.

“The system uses a new aircraft design with a smaller delivery droid that lowers packages gently to the ground, allowing for maximum accuracy, which makes it well-suited for urban settings like Kigali,” explains Kayitana.

This progress has been championed by Rwandan authorities, notably the Minister of Health, Dr Sabin Nsanzimana, who was recently named to the TIME100 Next list for his work in strengthening Rwanda’s health system through data-driven decision-making and innovation.

Under his leadership, Rwanda has benefitted from the impact of the integration of technology into healthcare delivery, allowing for improved and more reliable access to essential services.

The introduction of the urban delivery system in Kigali will address the high concentration of healthcare demand in the capital, enabling fast and precise deliveries within dense city environments.

“Introducing P2 in Rwanda means the country will be the first in Africa to deploy this type of urban autonomous logistics system,” Kayitana tells us.

“It will expand the range of deliveries that can be supported, improve response times in cities, and further integrate autonomous delivery into everyday healthcare and commercial logistics.”

LONG-RANGE COVERAGE

The new long-range distribution centre in Karongi is built on the border between Rwanda and the Democratic Republic of the Congo (DRC), intended as a symbol of peace between the two countries.

Its overall goal is to expand delivery capacity, expected to serve approximately 200 health posts and 60 major health facilities, reaching more than 2.9 million people.

“Together with the other hubs, it will help deliver full nationwide coverage, allowing Zipline’s network to support more than 11 million people across Rwanda,” informs Kayitana.

The addition of a third hub guarantees the provision of long-range coverage across the country, ensuring even remote and hard-to-reach communities can receive critical medical supplies quickly.

By integrating this connected network into national health systems, Rwanda is building a logistics infrastructure that ensures essential medicines and supplies can reach communities quickly and reliably, regardless of location.

The new AI and robotics testing facility, meanwhile, will serve as Zipline’s first R&D hub outside the US.

“This facility will allow us to test our technology in a range of real-world conditions, including different climates and terrain, helping improve the reliability and performance of aircrafts and systems globally,” Kayitana insights.

“It will also support the development of local talent by creating opportunities to work directly on advanced robotics and AI systems.”

INFLUENCE BEYOND LOGISTICS

Rwanda is demonstrating that autonomous delivery works at national scale, and in real-world conditions, as part of a government-led system.

“Independent research has increasingly validated the transformative power of this system, demonstrating that its influence extends far beyond mere logistics,” notes Kayitana.

“By optimising the delivery of critical goods, it has fundamentally reshaped supply chain efficiency – drastically reducing waste and theft whilst virtually eliminating the risk of stockouts.”

The impact on public health is even more profound, representing some of the most significant outcomes ever documented through a supply chain intervention.

Data confirms a staggering 56 percent reduction in maternal mortality and a 42 percent decrease in zero-dose prevalence.

Zipline is the most cost-effective immunisation intervention and one of the most cost-effective maternal health interventions on record.

Beyond these clinical milestones, the system serves as a powerful engine for economic stability.

“By creating hundreds of local jobs and safeguarding the health of the workforce, it generates tens of millions in annual economic growth, proving that a resilient supply chain is the essential foundation for a thriving society,” Kayitana closes.

The post Zipline Rwanda : Autonomous Delivery Across Rwanda appeared first on Healthcare Outlook.

MENTAL HEALTH MATTERS

Mental health is deeply connected to every aspect of a person’s life, from physical health to relationships, education, and workforce productivity.

Promoting it is therefore critical, especially amid the ongoing mental health crisis in the US, for which Mental Health Awareness Month serves as an important reminder each May.

However, the reality is that mental health and wellness should be a national priority every single day.

Meaningful progress has been made in reducing the stigma surrounding mental health issues, but too many individuals and families still face barriers to accessing care or feel hesitant to seek help.

“National awareness efforts play a vital role in normalizing conversations, encouraging early intervention, and reinforcing the importance of evidence-based mental health care,” emphasizes Brian Setzer, Chief Executive Officer of Newport Healthcare (Newport) – a leading provider of evidence-based behavioral health treatment for youth, young adults, and families.

“At a broader level, promoting mental wellness strengthens communities; when people have access to the right support at the right time, outcomes improve for individuals and families. Mental Health Awareness Month helps shine a light on that collective responsibility and the work that still needs to be done.”

Newport supports Mental Health Awareness Month by sharing resources throughout May with its audience of mental health professionals, past and current patients, and families.

The company conducts continuing education webinars and promotes the awareness month on its social media channels to highlight specific mental health trends and share inspirational stories of hope.

Various events are also held at Newport programs across the country for employees and patients to celebrate mental health and well-being.

“But really, every month is Mental Health Awareness Month at Newport,” acknowledges Setzer.

“We are focused year-round on sharing information, reducing stigma around treatment, and increasing access to care for young people and families.”

CONTINUUM OF CARE

The full continuum of care at Newport includes nationwide residential services, partial hospitalization programs (PHPs), and intensive outpatient programs (IOPs) for mental health and substance use disorders, as well as psychiatric inpatient services.

Newport’s family-centered, integrated approach fosters sustainable healing from a foundation of compassionate care and clinical expertise.

“Our stated mission is to provide results-driven, clinically integrated behavioral healthcare to individuals and families – creating hope, sustainable healing, and resiliency,” Setzer outlines.

Newport’s vision is to be the transformative leader in behavioral healthcare, focused on increasing access, driving innovation, and fostering authentic connections that inspire hope.

The company currently has residential treatment programs in eight states: California, Connecticut, Massachusetts, Minnesota (MN), North Carolina, Utah, Virginia, and Washington.

It also has outpatient treatment programs in each of those states, along with Georgia, Maryland, Pennsylvania, and Wisconsin, as well as an inpatient hospital in Brooklyn Park, MN.

“We have over 3,500 dedicated employees across the US. Our workforce of skilled and compassionate individuals is integral to the important, life-changing work we do,” Setzer says.

INNOVATIVE TECHNOLOGIES

Newport has expanded into new markets and added to its service offerings over the past few years.

This includes developing a learning health system, using valuable data gathered over many years to improve care quality as the company grows – by infusing best practices at scale and improving reliability in its outcomes.

“We continue to expand our service offering with a commitment to excellence and leading with innovation as patient needs evolve in each region across the US,” affirms Jameson Norton, MBA, FACHE, Chief Operating Officer.

Moreover, Newport is leaning into various technologies both in the delivery of care and the care itself.

For adult patients with treatment-resistant depression, the company’s PrairieCare division in Minnesota has deployed transcranial magnetic stimulation (TMS), a US Food and Drug Administration (FDA)-approved intervention that gives patients who have struggled for years an opportunity for relief.

Newport’s outcomes data shows that more than half of their TMS patients experience 50 percent improvements in their depression symptoms.

“We have also built out technologies that allow us to analyze data, patterns, and outcomes, providing us with tailored approaches to treatment at the individual level,” says Chief Innovation and Optimization Officer, Dr. Brent Nelson, MD.

In addition to offering innovative services like TMS, Newport is embracing the artificial intelligence (AI) revolution – to assist rather than replace humans.

“There is more demand for mental health services than can be possibly managed by our existing workforce. We must work smarter to be able to let our workforce focus on human connection, interaction, and healing, and use our AI assistants to help us get the busy work of healthcare accomplished in automated ways,” insights Nelson.

“We can deploy innovations around data gathering, writing documentation, providing assistants to facilitate real-time, continuous communication, and automated tracking of things that need to be accomplished in the context of care.”

The goal is to make the experience even more of a human connection, with AI working in the background to ensure Newport is meeting the highest levels of quality and safety.

This has also provided the company with significant insight into its data around outcomes and measures.

“In the past, it would have taken an army of statisticians to manage and analyze our data. Now, with AI assistants, we can put that power directly in the hands of our healthcare experts to allow them to find actionable patterns in their data,” Nelson enthuses.

CLINICAL COMPLEXITY

Mental health treatment is not one-size-fits-all, and the populations Newport serves are increasing in clinical complexity.

“Expanding our capabilities allows us to meet people where they are, with care that is clinically appropriate and proven to be effective,” Norton notes.

As the demand for mental health services continues to grow, so does the responsibility to ensure care is accessible and adaptable.

That means investing in a full continuum of care, developing specialized programming, and being intentional about addressing gaps that have historically limited access to quality treatment.

“Accessibility and affordability are essential to expanding care in this country. Whereas mental health treatment 15 years ago was prominently private pay – meaning it was paid directly out of pocket by families – they are increasingly turning to their insurance provider to pay for care,” observes Norton.

“Partnering with insurance providers helps families access quality healthcare much more easily. We currently accept most major insurances and are actively adding more – this is a priority for families and for Newport.”

Adapting to the changing mental health landscape in the US is essential. The needs of children, teenagers, and young adults are evolving rapidly, influenced by factors like technology, social dynamics, academic pressure, and broader societal uncertainty.

At the same time, there is increased acuity, earlier onset of symptoms, and more complex co-occurring conditions.

“If we don’t evolve alongside those changes and diversify our capabilities, we risk falling short of what patients and families truly need,” Norton warns.

“That means continuously reassessing how care is delivered, expanding access points, and integrating new, evidence-based approaches that reflect both clinical advancements and real-world challenges.”

This also requires a willingness to listen to patients, families, and clinicians on the front lines and use that insight to inform innovation.

Whether it’s enhancing specialized programming, strengthening early intervention, or leveraging data to guide treatment, adaptability is what allows Newport to stay effective and relevant.

“By staying responsive to the changing mental health landscape, we can ensure the care we provide remains impactful, accessible, and aligned with the realities families are facing right now,” Norton sets out.

OUTCOMES RESEARCH

Newport is proud of its focus on measurement-based care programs and long-standing commitment to outcomes research.

The company has a dedicated Center for Research and Innovation focused on tracking and analyzing its treatment outcomes.

Recent data highlights the effectiveness of the company’s treatment programs, showing patients experience measurable improvements in depression, anxiety, suicide risk, well-being, family attachment, general functioning, and other measures.

“Independently reviewed by a third-party academic consultant, this research is evidence that our comprehensive treatment model creates transformative, lasting results for adolescents and young adults in both residential and outpatient care,” acclaims Norton.

“Outcomes studies are essential because they ensure we’re not just providing care – we’re delivering care that truly makes a difference.

“In behavioral healthcare, it’s critical to move beyond intention and rigorously measure impact. Our outcomes data allows us to evaluate what’s working, identify opportunities to improve, and hold ourselves accountable to the patients and families we serve,” he adds.

The data is used to inform every aspect of treatment and helps Newport to refine clinical models, tailor interventions to better meet the needs of specific populations, and ensure its approaches are grounded in evidence.

This continuous feedback loop allows the company to adapt in real time and stay aligned with best practices in the field.

“We also track how patients are doing after they leave our care, and we can see they maintain improvements months later and are functioning better in multiple aspects of their daily lives, such as relationships, school, work, and family connection,” Norton states proudly.

Just as important, outcomes data builds trust. For families making incredibly important decisions about care, having transparency into proven results provides confidence that they are choosing a program dedicated to quality, accountability, and long-term success.

“Ultimately, our focus on outcomes is about ensuring every young person who comes to us has the best possible opportunity to heal and thrive,” Norton says.

SPECIALIZED OCD CARE

For children and adolescents struggling with obsessive-compulsive disorder (OCD), Newport has developed specialized care, recognizing both the complexity of the condition and profound impact it can have on a young person’s development and daily life.

About 20 percent of people with OCD experience onset at age 10 or earlier. It is also often misunderstood or misdiagnosed, which can delay effective treatment, so early identification and the right clinical approach are critical.

“Our programs are grounded in evidence-based practices, particularly exposure and response prevention (ERP) therapy, which is widely considered the gold standard for treating OCD,” Norton tells us.

“What sets our approach apart is how we integrate this modality into a broader, individualized treatment plan that also addresses co-occurring conditions, family dynamics, and the unique developmental needs of each patient.”

Newport also places a strong emphasis on family involvement, equipping parents and caregivers with the tools and understanding they need to support their child’s progress outside of treatment.

“Ultimately, our goal is not just symptom reduction, but helping young people regain a sense of control, confidence, and the ability to fully engage in their lives,” he assures.

CLINICALLY CREDIBLE

Clearly, Newport is uniquely positioned to serve adolescents and young adults on a national basis across the full continuum of care.

“We are heavily focused on refining our care delivery models to create a partnership with our patients, their families, and their insurance providers to ensure treatment accessibility, affordability, and best-in-class outcomes,” Setzer informs us.

Looking ahead, the company is committed to improving timely and efficient access to care in every market while advancing its clinical outcomes and its position as a trusted and clinically credible leader in behavioral healthcare.

“Part of fulfilling this promise is ensuring Newport is a great place to work for our employees, allowing them to grow as professionals in our team-based care model, career ladders, and training opportunities,” Norton shares.

Newport’s central focus is to deliver the highest quality of care through understanding and respect for the individual’s journey.

“We utilize deep connections, team-based approaches, and focused treatments based on modern, research-proven techniques,” Nelson closes.

“The goal is to get the individual back to health and back to their life in a way that supports their full recovery.”

The post Newport Healthcare : Mental Health Matters appeared first on Healthcare Outlook.

SLEEP ON DEMAND

Foundational to both physical and emotional health, sleep is crucial to the ability to perform at your best. Not only does it play a critical role in cognitive functions, but it also aids in tissue repair, muscle growth, and immune system strengthening – making high-performance sleep essential for overall well-being.

Elemind is here to help people take back control of their sleeping patterns.

As a neurotechnology company building the first clinically validated, non-invasive platform that can read and write to the brain in real-time, Elemind combines advanced neuromodulation algorithms and artificial intelligence (AI) to guide the brain from one state to another just using acoustic neurostimulation.

“We launched commercially in 2024 with a wearable electroencephalogram (EEG) headband designed to help people fall asleep and fall back to sleep significantly faster without drugs,” introduces Meredith Perry, co-Founder and CEO.

“Whereas every other wearable just reads, Elemind reads and writes. We don’t just track the brain – we change it directly,” she asserts.

Elemind’s industry-changing product is built on direct, real-time interface with the brain. Using high-fidelity EEG, the company continuously reads neural activity and applies precisely timed acoustic stimulation individualized to each person’s brain dynamics.

The system models a user’s neural state moment by moment and intervenes at exactly the right phase of ongoing brain activity. This closed-loop approach, grounded in peer-reviewed clinical research and protected by patents, allows Elemind to influence sleep at the level where it naturally occurs – the brain itself.

The company views this as a new class of non-invasive medicine, one that uses sound, timing, and neuromodulation to produce measurable physiological effects.

“Elemind is building infrastructure, not a gadget,” emphasizes Perry.

“We are laying the foundation for how humans will interact with their own brains safely, non-invasively, and intelligently. Sleep is where that journey begins, but it’s not where it ends.”

THE FUTURE OF SLEEP

Elemind has pioneered a practical, wearable implementation of closed-loop neuromodulation, combining high-fidelity EEG, low-latency signal processing, AI, and precisely phase-locked acoustic stimulation in a consumer-ready device.

“Critically, our stimulation is not static. It is timed to the user’s own brainwaves, down to the millisecond,” Perry details.

This real-time phase targeting allows Elemind to influence sleep onset and other neural transitions effectively and is supported by multiple peer-reviewed studies. No other consumer-available system operates at this level of temporal and physiological precision.

The company is demonstrating that sleep can be treated as a modifiable neural process rather than something one merely observes or sedates.

“By gently intervening at the right time, we can help people fall asleep faster, improve sleep continuity, and potentially enhance deeper stages of sleep without pharmaceuticals,” expands Perry.

Beyond sleep quality, the implications include better next-day performance, improved recovery, and reduced reliance on sleep medications. More broadly, Elemind is helping shift health and wellness toward targeted, non-invasive, and adaptive interventions.

BEYOND SLEEP

Elemind’s vision of ‘beyond sleep’ exemplifies its ambition to unlock the brain’s potential, pushing the boundaries of what’s possible in neurotechnology and sleep science.

“Sleep is our entry point, not our endpoint. We chose sleep because it gives us long, high-quality neural data every night and a clinically meaningful problem where real-time modulation matters,” Perry informs.

Beyond sleep, the vision is a platform for the brain. Clinical trials using Elemind’s technology show efficacy in improving memory consolidation, recovery, neurological disorders such as tremors, and other brain state-dependent conditions.

Long-term, Elemind is building an adaptive neural system that learns from each interaction with the brain and improves over time.

To achieve this, the company is working on a variety of projects to expand its capabilities. One such initiative is the Deep Sleep Stimulation, which builds on Elemind’s work on sleep onset and targets slow-wave activity during rest. Its goal is to enhance sleep depth and the brain’s natural restorative and memory-related processes.

“This work is also being extended into clinical research. We recently received a USD$6.3 million grant from the Medical Research Council (MRC) to study how enhancing deep sleep may support memory consolidation in people with dementia,” details Perry.

“It’s an important step in understanding how targeted, non-invasive brain modulation during sleep could have meaningful neurological benefits beyond sleep quality alone.”

WHERE THE JOURNEY BEGINS

Elemind is proudly built by a small, deeply technical team that spans neuroscience, electrical engineering, machine learning (ML), and applied clinical research. The team includes industry engineers and world-class academic collaborators, and has multiple peer-reviewed clinical trials published in top scientific journals.

Its scientific co-Founders include Dr. Ed Boyden from the Massachusetts Institute of Technology (MIT), a pioneer in neurotechnology, and Dr. Nir Grossman from Imperial College London, whose work has helped define modern non-invasive brain stimulation.

Co-Founder and CTO, Dr. David Wang, also holds a PhD in AI from MIT and leads the development of the company’s real-time neural modeling and closed-loop systems.

“I come from a background in astrobiology and wireless power, which has helped shape how we think about building precise, scalable technology for complex biological systems,” explains Perry.

Elemind also works closely with Dr. Heather Read, a professor at the University of Connecticut, whose expertise in sleep and neurophysiology informs the company’s clinical direction.

Supporting the science behind Elemind is a lean, highly effective team of engineers, operations leaders, and marketers who focus on translating rigorous research into products people can actually use.

“Together, our team is pushing the boundaries of what non-invasive neurotechnology can do, while staying grounded in real-world impact,” prides Perry.

As Elemind continues to look ahead towards a successful future of promoting deep, regenerative sleep, its priorities comprise expanding clinical validation, launching new sleep-stage specific features, and scaling access to the technology responsibly.

“We are also deepening partnerships across healthcare, wellness, and performance, while investing heavily in our core neuromodulation platform,” she concludes.

The post Elemind : Sleep On Demand appeared first on Healthcare Outlook.

AI-DRIVEN ADVANCEMENT IN PARKINSON’S CARE

Cellular Intelligence has entered into an agreement with Novo Nordisk to acquire global rights to the pharmaceutical giant’s clinical-stage cell therapy programme for Parkinson’s disease.

The agreement marks a significant milestone for Cellular Intelligence as it looks to apply its proprietary AI-native platform to accelerate clinical development, manufacturing, and the path towards commercialisation for the programme, which is currently in a first-in-human Phase 1/2 clinical trial.

Importantly, the therapy has already received FDA Fast Track Designation and IND clearance for further clinical development, underscoring its potential as a meaningful disease-modifying treatment for people living with Parkinson’s disease.

As part of the arrangement, Novo Nordisk will also make an equity investment into Cellular Intelligence and remain eligible for future milestones and royalties.

SCALING CELL THERAPY THROUGH AI

At the centre of the collaboration is Cellular Intelligence’s AI-native platform, which combines proprietary multiplexing technologies with a foundation model trained on data spanning millions of unique perturbation conditions.

The company believes this approach can significantly compress traditional cell therapy development and manufacturing timelines whilst reducing costs and improving scalability – key barriers that have historically limited wider commercial adoption within regenerative medicine.

The Parkinson’s programme itself focuses on an allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy, designed to address the growing global burden of neurodegenerative disease.

Beyond the immediate programme, Cellular Intelligence also expects the clinical and manufacturing data generated through development to further strengthen its foundation model, potentially enabling wider applications across cell therapy and regenerative medicine in the future.

STRENGTHENING CLINICAL LEADERSHIP

To support the programme’s continued advancement, Cellular Intelligence has appointed Nuno Mendonça, M.D., as Chief Medical Officer.

A board-certified neurologist, Dr. Mendonça brings extensive experience from senior clinical development roles at Bial, AbbVie, and Novartis Gene Therapies, spanning both early- and late-stage neuroscience and rare disease programmes across North America and Europe.

The appointment reflects Cellular Intelligence’s ambitions to rapidly scale the programme’s clinical progression whilst leveraging its AI capabilities to streamline manufacturing and operational efficiency.

Operating under the legal entity Somite Therapeutics, Cellular Intelligence describes itself as an AI-native TechBio focused on building a universal foundation model of cell signalling to better understand, predict, and ultimately control cellular behaviour.

Headquartered in Boston, the company has raised more than USD$60 million to date from investors including Khosla Ventures, CZI, SciFi VC, and AMD Ventures, as it continues expanding its clinical-stage regenerative medicine platform.

The post Novo Nordisk and Cellular Intelligence Advance Parkinson’s Therapy appeared first on Healthcare Outlook.

Lilly Increases Indiana Manufacturing Commitments to More Than $21 Billion

The latest commitment brings Lilly’s total Indiana capital expansion investment since 2020 to more than $21 billion, reinforcing the company’s long-term focus on scaling U.S.-based pharmaceutical production capacity to support growing demand for advanced therapies and metabolic disease treatments.

The investment will support expanded capabilities at Lilly Lebanon API, one of the company’s future active pharmaceutical ingredient production facilities, and Lilly Lebanon Advanced Therapies, which officially opened this week.

Genetic Medicine Facility Marks New Phase in Advanced Therapy Manufacturing

Lilly Lebanon Advanced Therapies is the company’s first dedicated manufacturing facility focused on genetic medicines.

The site is designed to support both clinical and commercial-scale production of therapies targeting disease at the genetic level, including a range of advanced treatment modalities from early-stage development through large-scale supply.

According to Lilly, designing the facility required the development of new manufacturing processes without established commercial precedent, highlighting the growing complexity of next-generation pharmaceutical production infrastructure.

The facility is the first of three planned manufacturing sites on the Lebanon campus, which will also include Lilly Lebanon API and the Lilly Medicine Foundry.

Expanded Capacity Supports Obesity and Diabetes Drug Production

The Lebanon API site is expected to manufacture several of Lilly’s key metabolic disease products, including:

• Zepbound® (tirzepatide) for weight management
• Mounjaro® (tirzepatide) for type 2 diabetes
• Foundayo™ (orforglipron), Lilly’s FDA-approved once-daily weight loss pill
• Retatrutide, an investigational obesity and cardiometabolic therapy currently in late-stage development

When completed, the Lebanon API facility is expected to become the largest API production site in U.S. history.

“From genetic medicines that could one day prevent disease at its source, to Foundayo, a pill making weight loss treatment accessible to millions, we are not just discovering the medicines of the future—we are building the world’s most advanced plants to make them,” said David A. Ricks, Lilly chair and CEO.

Pharmaceutical Manufacturing Expansion Strengthens U.S. Supply Chain Strategy

The announcement reflects broader industry efforts to strengthen domestic pharmaceutical manufacturing capacity and reduce supply chain risk through increased U.S.-based production.

U.S. capital expansion commitments since 2020 now total more than $50 billion, supported by policies promoting domestic manufacturing investment and the company plans to begin construction on several newly announced U.S. manufacturing facilities later this year.

Indiana Governor Mike Braun said the investment reinforces the state’s position within the life sciences manufacturing sector.

“With this investment in Lebanon and across the state, Indiana is reinforcing its position as a prime destination for life sciences and advanced manufacturing, spanning innovation, production and global distribution,” Braun said.

Manufacturing Investments Deliver Broader Economic Impact

According to findings from an upcoming Indiana University Kelley School of Business report cited by Lilly, the company accounts for 70% of Indiana’s pharmaceutical GDP, with every Lilly job supporting more than two additional jobs statewide.

Lilly also estimates that every dollar it spends locally generates up to four dollars in additional regional economic activity.

The Lebanon manufacturing campus has become a central component of Lilly’s domestic production strategy as pharmaceutical companies continue increasing investment in advanced biologics, obesity therapies, and next-generation genetic medicines.

“Lilly’s sustained investments since 2020 underscore the growing strength of Indiana’s life sciences sector,” said Indiana University President Pamela Whitten. “Progress at this scale is possible only through robust partnerships.”

The post Eli Lilly Expands North America Indiana Manufacturing Investment with Genetic Medicine Facility appeared first on Healthcare Outlook.

Wearables Move Further into Preventive Healthcare

Samsung Electronics has announced the results of a joint clinical study with Chung-Ang University Gwangmyeong Hospital demonstrating the potential for smartwatch-based prediction of vasovagal syncope (VVS), commonly known as fainting.

The research used biosignal data collected from the Samsung Galaxy Watch6 and analysed heart rate variability patterns through an AI algorithm to identify signs of an impending fainting episode.

According to the study, the model was able to predict episodes up to five minutes in advance with an accuracy rate of 84.6%.

Addressing Risks Associated with Vasovagal Syncope

Vasovagal syncope occurs when heart rate and blood pressure suddenly drop, often triggered by stress or other physiological factors, leading to temporary loss of consciousness.

While fainting itself is generally not life-threatening, falls associated with episodes can result in serious secondary injuries, including fractures and concussions.

“Up to 40% of people experience vasovagal syncope over their lifetime, with one-third experiencing recurrent episodes,” said Junhwan Cho, Professor of Cardiology at Chung-Ang University Gwangmyeong Hospital.

“An early warning could give patients advance time to get into a safe position or call for help, which would dramatically reduce the incidence of secondary injuries.”

Clinical Validation Using Consumer Wearables

The study evaluated 132 patients with suspected VVS symptoms during induced fainting tests.

Researchers used the smartwatch’s photoplethysmography (PPG) sensor to collect heart rate variability data, which was then processed through an AI model trained to detect physiological changes preceding fainting episodes.

The system achieved a clinically meaningful sensitivity of 90% and specificity of 64%, supporting the feasibility of wearable-based prediction systems in healthcare settings.

Samsung said the findings represent the first study to demonstrate the potential for a commercial smartwatch to provide early prediction of syncope.

Expanding the Role of Digital Health Monitoring

The findings reflect a broader trend toward integrating consumer-grade wearable devices into preventive healthcare and remote patient monitoring strategies.

“This study is an example of how wearable technology can help shift healthcare from being designed for ‘post-care’ to a model of ‘preventive care,’” said Jongmin Choi, Head of Health R&D Group at Samsung’s Mobile eXperience Business.

“We are committed to driving technological innovation that empowers our users to lead healthier everyday lives.”

Real Implications for Healthcare Providers

For healthcare providers, the study suggestss the increasing clinical potential of wearable biosignal monitoring in early intervention and patient safety applications.

The ability to identify high-risk events before symptoms escalate could support new models of remote monitoring, particularly for patients with recurrent syncope conditions or elevated fall risk.

For digital health developers, the research also adds the growing convergence of AI analytics, biosensors and consumer devices in preventive care pathways.

The post Can a Smart Watch Predict Fainting? Samsung Study Demonstrates Preventative Healthcare Tech Solution appeared first on Healthcare Outlook.

This is a working conference. Less theory, more application. Expect practical insight on how omnichannel strategy is actually being executed across global and local markets – with measurable impact.

Conference: Pharma Omnichannel Excellence
Date: 3rd June 2026
Venue: One America Square, London

WHAT THIS EVENT IS BUILT AROUND

The agenda is tightly aligned with the challenges pharma teams are actively dealing with:

• AI-powered omnichannel transformation
  Practical use of AI to improve targeting, forecasting, and decision-making
• Hyper-personalisation and precision segmentation
  Balancing relevance with compliance in HCP and patient engagement
• Data, measurement, and ROI
  Moving beyond surface metrics to demonstrate commercial impact
• Global vs local execution
  Aligning central strategy with regional realities and compliance constraints
• Content that connects
  Delivering consistent messaging across face-to-face, digital, and emerging channels
• Social media in pharma
  Navigating compliance while maintaining authenticity and engagement
• Customer feedback loops
  Turning insight into continuous improvement across channels

FORMAT AT A GLANCE

• 25+ speakers from pharma marketing, commercial, and medical teams
• 3 panel discussions tackling shared industry challenges
• 9 international perspectives shaping global strategy
• 2+ hours of networking built into the day
• Interactive Q&A and live polling throughout

This isn’t a passive sit-and-listen setup. It’s designed for participation and peer exchange.

WHY IT MATTERS

Omnichannel in pharma has moved past experimentation. The pressure now is on execution, measurement, and proving ROI.

This event focuses on:

• Connecting strategy to real-world delivery
• Aligning internal teams across commercial, marketing, and medical
• Understanding how AI and data are reshaping engagement models
• Building approaches that stand up to compliance scrutiny

For most teams, this is where friction sits. That’s what this conference is addressing.

WHO SHOULD ATTEND

• Pharma marketing leaders
• Commercial strategy teams
• Medical affairs professionals
• Digital and omnichannel specialists

If your role touches customer engagement, channel strategy, or performance measurement, this is directly relevant.

COMMERCIAL AND NETWORKING VALUE

• 97% satisfaction rate from the previous event
• Access to senior decision-makers across pharma
• Peer-led discussions with no sales pitches from the stage
• Real case studies with implementation detail

It’s positioned as a high-density day – insight, connections, and takeaways without wasted time.

OPPORTUNITIES TO GET INVOLVED

There are multiple ways to participate beyond attending:

• Speaking opportunities
• Sponsorship and exhibition packages
• One-to-one meetings with attendees

This is particularly relevant for organisations supporting pharma with technology, data, or marketing solutions.

REGISTRATION AND GROUP OFFERS

Group bookings are incentivised:

• Send 4 delegates for the price of 3
• Or 3 delegates with the third at half price

(Available for in-house pharma teams)

CONTACT DETAILS

For attendance, partnerships, or further information:

• https://pharmamarketingconference.com
• +44 (0)20 3479 2299
• info@pharmamarketingconference.com

ABOUT THE ORGANISER

Delivered by Global Insight Conferences, a specialist in industry-led events designed around practical value and high-quality networking.

If you’re working on omnichannel strategy in pharma right now, this sits firmly in the “useful day out of the office” category rather than a generic conference slot.

The post Pharma Omnichannel Excellence Conference | 3rd June 2026 | London appeared first on Healthcare Outlook.

Written in collaboration with patients, advocacy groups, and the pharmaceutical industry, the event is designed to explore how organisations can improve patient experiences, strengthen trust, and deliver meaningful healthcare outcomes through more collaborative and responsive engagement strategies.

Conference: Patient Centricity & Engagement Conference
Date: 24th June 2026
Venue: The Grand Connaught Rooms, London

Defining the Future of Patient-Centric Innovation

As healthcare organisations continue to navigate rapid technological change, increasing patient expectations, and growing pressure to demonstrate measurable impact, patient centricity has become a critical strategic priority across the pharmaceutical industry.

This year’s conference agenda focuses heavily on actionable engagement strategies, AI adoption, patient feedback integration, and multi-stakeholder collaboration.

Topics set to dominate discussions include:

• AI in patient engagement and patient experience strategies
• Patient trust and transparency
• Patient involvement in HTA processes
• Engagement in clinical trials and treatment pathways
• Measuring the real impact of patient engagement
• Advocacy collaboration and stakeholder alignment
• Internal transformation to embed patient-first thinking

The conference aims to move beyond theory and provide attendees with practical insights they can apply directly within their organisations.

AI, Trust, and the Next Phase of Patient Engagement

One of the major themes for 2026 will be how pharmaceutical organisations can strategically integrate AI into patient engagement without compromising trust, empathy, or accessibility.

Dedicated sessions will examine:

What meaningful AI-driven patient engagement should actually look like
How to balance innovation with ethical considerations
Using technology to personalise engagement while reducing patient burden
Building systems that listen and adapt to real patient needs

Alongside technology discussions, the event will also focus on restoring and strengthening patient trust through better communication, earlier collaboration, and more inclusive engagement models.

Interactive Panels and Real-World Perspectives

The conference programme includes four interactive panel discussions covering:

• Patient Perspectives in Treatment
• Patient Engagement in Clinical Trials
• Patient Involvement in HTA
• Stakeholder Collaboration

Attendees will hear directly from patients and advocacy groups about their experiences interacting with industry, what they believe still needs to improve, and where genuine opportunities for collaboration exist.

More than 10 patient representatives and advocates are expected to participate across the agenda.

Industry Speakers and Case Studies

The event will feature fresh case studies and insights from organisations including:

• Bristol Myers Squibb
• Ipsen
• Bayer
• Jazz Pharmaceuticals
• Pfizer
• Macmillan Cancer Support

Organisers describe the event as a practical, discussion-led environment focused on genuine learning rather than sales presentations.

Networking and Collaboration Opportunities

In addition to the conference sessions, attendees will benefit from two hours of dedicated networking opportunities designed to encourage meaningful connections across the patient engagement ecosystem.

Who is the conference for?

The event attracts professionals working in:

• Patient engagement
• Patient advocacy
• Medical affairs
• Commercial strategy
• Market access
• Clinical operations
• Patient experience
• Digital health and engagement

Group discounts are available for organisations sending multiple delegates.

Partnership and Sponsorship Opportunities

Companies interested in increasing visibility within the patient engagement and pharmaceutical space can also explore sponsorship, exhibiting, speaking, and one-to-one meeting opportunities.

Packages include exhibition stands with delegate passes and networking access throughout the event.

REGISTRATION AND GROUP OFFERS

Group bookings are incentivised:

• Send 4 delegates for the price of 3
• Or 3 delegates with the third at half price

(Available for in-house practitioners only) More details

Contact Details

• patientengagementconference.com
• +44 (0)20 3479 2299
• partner@patientengagementconference.com

The post Patient Centricity & Engagement Conference | 24th June 2026 | London appeared first on Healthcare Outlook.

TURBOCHARGE YOUR MARKETING WITH BUILT-IN TOOLS

Reaching the right clients at the right time can make or break your revenue goals. Integrated marketing tools give you direct access to your client base through email campaigns, SMS promotions and re-engagement messages.

Instead of paying for separate marketing platforms, you can launch targeted campaigns from the same system that manages your appointments and client data.

The salon industry is expected to grow by 7.90 percent annually, on average, through 2034. Capturing your share of that growth means staying visible to both current and potential clients. Built-in marketing tools let you announce new services, share seasonal promotions and remind clients it’s time for their next appointment.

When you can use software to get more salon clients through integrated campaigns, you keep more of your marketing budget working directly for your business.

DRIVE REPEAT BUSINESS WITH MEMBERSHIP OR LOYALTY PROGRAMS

One-time clients pay the bills, but loyal regulars build sustainable revenue. Many salon software platforms allow the creation of loyalty or membership programs that reward clients automatically based on dollars spent or visits completed. Every service they book earns points toward their next treatment or retail purchase.

Traditional punch cards require manual tracking and often get lost or forgotten. Automated programs eliminate that friction entirely. Your software tracks every transaction and applies rewards seamlessly.

Clients can see their progress through your booking portal, and they’re more motivated to return when they’re close to earning their next reward. This creates a predictable cycle of repeat visits that stabilizes your revenue month after month.

INCREASE AVERAGE SALES WITH ONLINE ADD-ONS

Industry experts recommend that salons allocate about 3 percent of gross income to marketing. Smart salon software to increase profit often includes built-in e-commerce for add-ons and gift cards, helping you maximize the return on that investment

For example, the software may suggest complementary services during the online booking process. A client scheduling a haircut sees an option to add a deep conditioning treatment or scalp massage with a single click.

These low-friction upsells happen before the client ever walks through your door. The same principle applies to gift card sales as add-ons during booking. This can turn your website into a revenue generator even when your salon is closed.

MAXIMIZE YOUR BOOKINGS WITH OPTIMIZED SCHEDULING

Keeping your calendar full protects revenue that empty chairs lose. Advanced scheduling features meet clients where they are. People book appointments when the idea occurs to them, whether that’s late at night or early Sunday morning when your salon is closed.

Software with online booking capabilities lets clients secure their spot at any time of day or night. You get more salon clients with 24/7 software because you capture every opportunity regardless of business hours.

Smart calendar management identifies gaps in your schedule and can suggest optimal booking times to keep your team consistently busy. Every hour your professionals spend working instead of waiting translates directly into higher revenue.

Meanwhile, automated reminders can also reduce no-shows by sending confirmations via text or email before each appointment.

OFFER FLEXIBLE AND CONVENIENT PAYMENT METHODS

The checkout experience shapes how clients remember their visit. Software that integrates modern payment options makes transactions smooth and effortless.

Contactless payments, mobile wallets and securely saved payment cards let clients complete their purchase in seconds.

Faster checkout frees your team to dedicate more time to the next client. When the payment experience feels convenient and current, clients associate that positive feeling with your entire brand. They’re more likely to rebook and recommend your salon to friends when every touchpoint feels professional and easy.

TAKE CONTROL WITH SMART INVENTORY MANAGEMENT

Retail products and professional inventory represent significant capital investment. Poor inventory management ties up cash in slow-moving stock while popular items run out at the worst possible time.

Many software platforms offer smart inventory features that track product usage in real time and can automatically trigger reorder alerts when supplies run low.

You can identify which retail products generate profit and which ones sit on shelves collecting dust. This is an often-overlooked way that salon software can increase profit.

When your bestselling products are always in stock, and your capital focuses on items that move, your retail revenue becomes a reliable profit centre.

RECLAIM YOUR TIME THROUGH SMART TASK AUTOMATION

Every hour your team spends manually calculating payroll, compiling sales reports or confirming appointments is time they could spend with paying clients.

Task automation handles routine processes in the background. Payroll calculations happen automatically based on hours worked and commission structures.

Sales reports are generated on schedule while appointment confirmations are sent at the optimal time.

When you free your team from repetitive administrative tasks, they can reinvest that time in activities that actually drive revenue. Your managers can focus on business strategy, and your stylists can take more appointments.

ELIMINATE BOTTLENECKS THROUGH RESOURCE MANAGEMENT

Maximizing your team’s productivity matters, but physical resources can create bottlenecks just as easily as staffing constraints. Treatment rooms, specialised equipment and even shampoo stations become limiting factors when demand exceeds availability.

Resource management features let you track and allocate these physical assets alongside your team’s schedules. You can see at a glance when your most popular treatment room is available or when your high-demand massage equipment is booked.

This visibility helps you schedule more strategically and serve more clients. Every additional client you can accommodate because resources are optimized properly adds directly to your revenue.

HOW MEEVO DRIVES REVENUE FOR SUCCESSFUL SALONS AND SPAS

Meevo combines all of these features into a single platform built specifically for salons, spas and med spas. Salon leaders report excellent results.

That’s the kind of measurable impact that transforms salon software to increase profit from a nice-to-have into a strategic necessity.

The platform has won Beauty Launchpad’s “Best Salon Software” award 19 times and offers more than 150 industry-leading reports that give you complete visibility into your business performance.

From HIPAA-compliant features for med spas to yield management tools that adjust pricing based on demand, Meevo delivers the comprehensive capabilities that successful salon and spa owners need to compete and grow.

FREQUENTLY ASKED QUESTIONS ABOUT SALON SOFTWARE

1. What is the most important feature in salon software?
   It depends on your specific business goals and current challenges. However, robust reporting and analytics capabilities are universally valuable. Measurement drives improvement and detailed reports help you understand where growth opportunities exist.
2. How much should I expect to pay for salon software?
   Pricing varies significantly across the market. Some basic platforms offer free plans with limited features, and most offer tiered pricing according to your business size or number of locations.  Focus on return on investment rather than the price tag alone. Salon software that increases profit typically pays for itself many times over.
3. How can salon software help with employee burnout?
   Service industry professionals are prone to burnout from emotional labor and the constant demands of client interaction. Software that automates tedious administrative tasks reduces the cognitive load on your team. When staff members spend less time on backend paperwork and scheduling logistics, they experience less stress and can focus their energy on the creative, rewarding aspects of their work.

STYLING YOUR PATH TO PROFITABILITY

The right software represents an investment in sustainable growth. From marketing tools and loyalty programs to optimized scheduling, flexible payments, inventory control, resource management and task automation, there are many ways you can use software to get more salon clients and increase revenue from existing ones.

The salon and spa industry rewards businesses that combine exceptional service with operational excellence. Strategic software helps you achieve both.

The post Meevo : How the Right Software Can Drive Revenue Growth for Your Business appeared first on Healthcare Outlook.

ENABLING PHARMACEUTICAL SUPPLY CHAIN VISIBILITY

As demand for glucagon-like peptide-1 (GLP-1) therapies accelerates and direct-to-patient delivery becomes more common, pharmaceutical cold chains are being pushed into more complex and fragmented distribution models.

What was once a tightly controlled and highly predictable system is now under pressure from increased shipment volumes, more handoffs, and greater exposure to uncontrolled environments, particularly in the final stages of delivery.

For therapies that require strict temperature control and careful handling, this shift is exposing critical gaps in visibility and accountability.

Temperature excursions, handling inconsistencies, and limited oversight in the last mile can all compromise product integrity, while the rise of compounded alternatives is placing even greater emphasis on authentication and traceability at the item level.

Deepak Prakash, Vice President, Healthcare at Identiv, outlines how the company is helping address these challenges through sensor-enabled Bluetooth Low Energy (BLE) smart labels and digital identity solutions that bring continuous, item-level visibility to pharmaceutical logistics.

By enabling products to communicate their condition, movement, and provenance in real time, Identiv is helping manufacturers and logistics providers move beyond retrospective cold chain monitoring toward a more connected, intelligent, and accountable model.

Healthcare Outlook (HO): As the demand for GLP-1 doses continues to surge and the frequency of direct-to-patient delivery increases, what specific vulnerabilities has this shift exposed in the cold chain?

Deepak Prakash, Vice President, Healthcare (DP): The rapid adoption of GLP-1 therapies is reshaping how high-value pharmaceuticals move through the supply chain.

What was once a tightly controlled and predictable system now operates across a broader mix of environments, handoffs, and delivery models, including channels that reach patients directly.

That expansion is being driven by pure scale; JPMorgan projects GLP-1 usage in the US could reach 30 million patients by 2030, with the cold chain packaging market expected to reach $71.6 billion by 2034.

With volume and distribution complexity growing in tandem, the ability to maintain consistent oversight becomes more difficult.

The key vulnerability this exposes is fragmentation – products no longer move through a single, controlled pathway; they pass through a series of independent environments, each with its own workflows.

And as those touchpoints multiply due to GLP-1 demand, so do the chances for inconsistencies in handling and gaps in accountability, making it harder to confidently assess product integrity.

HO: With GLP-1 therapies requiring a strict 2 to 8°C temperature range, how significant is the risk in the final “last mile” environment – in terms of both temperature control and other variables – and what does the industry still underestimate about what happens between pharmacy dispatch and patient receipt?

DP: The last mile introduces more variability and less oversight than earlier stages of the supply chain. Delivery timelines can change, packages may be exposed to fluctuating conditions, and products often sit unattended before receipt.

For therapies with narrow temperature tolerances, even short deviations carry consequences, particularly when they go unnoticed.

The financial scale of cold chain failures reflects how persistent this challenge is. The biopharmaceutical industry loses an estimated $35 billion annually due to breakdowns in temperature-controlled logistics, with many incidents occurring during transit and handling.

What the industry tends to underestimate is how last-mile risk factors converge. Delays, handling variability, and environmental exposure all overlap.

By the time a product reaches the patient, there is often no clear way to verify exactly what it experienced along the way, creating a black box with direct implications for product integrity and patient safety.

HO: As compounded and alternative GLP-1 products enter the market, how is the definition of cold chain accountability evolving beyond temperature control to include item-level authentication and traceability, such as Identiv’s BLE-enabled smart labels?

DP: That black box problem is precisely what is pushing accountability beyond temperature alone.

With more product types entering more distributed channels, knowing that a shipment stayed cold is no longer sufficient; you need to know that the product is genuine, traceable, and intact at the item-level.

Identiv’s BLE-enabled smart labels, with customizable configurations, support this by assigning each unit a unique digital identity to continuously capture and transmit critical data throughout its journey.

This creates a persistent item-level record that travels with the product, enabling verification of condition, provenance, and integrity at critical handoff points, including delivery.

As visibility becomes continuous, accountability evolves from being a compliance function into a dynamic data-driven capability.

The same item-level intelligence that enables traceability also powers predictive, automated, and responsive supply chains, where risks are identified earlier, interventions occur in real time, and the journey of sensitive therapies is continuously optimized from origin to patient.

HO: From Identiv’s perspective, what does true end-to-end visibility actually look like in a modern pharmaceutical supply chain, and how are your technologies helping close the gaps that exist today?

DP: True end-to-end visibility means the ability to follow each unit from origin to patient with a clear and continuous item-level record of its condition, integrity, and chain of custody, with data that can be accessed and acted on in real time without relying on retrospective reconstruction.

One of the primary challenges in achieving this is interoperability. Information is captured at multiple stages, but it often resides in disconnected systems that don’t communicate effectively.

Without consistent data exchange between platforms, it becomes difficult to assemble a complete and reliable view of a product’s movement.

Identiv addresses this by anchoring visibility at the source. Sensor-enabled labels capture temperature, humidity, movement, and handling in real time, and through collaborations with partners like Tag-N-Trac, that information can be integrated into cloud-based platforms designed to convert raw data into value for specific applications, such as cold-chain.

This makes it accessible across both transit and storage environments as events occur.

For GLP-1 therapies specifically, this enables teams to confirm product integrity in real time and respond before issues reach the patient.

HO: Looking ahead – and as continuous condition monitoring becomes increasingly pertinent – where is Identiv seeing the strongest demand for innovation? Temperature monitoring, authentication, or integrated solutions that combine both?

DP: Integrated solutions, without question. The conversations we’re having are no longer about solving for temperature or authentication in isolation; organizations want a complete picture at the item level. Where did this product originate? How did it move? Was it ever compromised?

Delivering that level of visibility becomes more complex as these therapies move through highly distributed supply chains.

With GLP-1 access expanding, products are passing through more partners and environments, increasing the number of handoffs and potential points of risk.

In response, we’re seeing growing interest in layered security models that combine overt and covert protections; overt features enabling fast and intuitive authentication as products change hands, and covert elements providing a deeper layer of security tied to each unit’s digital identity to guard against diversion, tampering, and counterfeiting throughout the journey.

Together, these approaches enable a coordinated end-to-end accountability model that connects first-, middle-, and last-mile distribution, built to support pharmaceutical access at unprecedented scale.

Sustainability is also emerging as an important driver of innovation. When temperature-sensitive products fall outside required conditions, they are discarded, and that waste accumulates quickly.

It’s been estimated that up to 50 percent of vaccines are wasted globally, with cold chain failures being a major contributing factor.

Real-time insight into product movement and handling enables earlier intervention, helping curb avoidable loss and supporting the move toward more efficient, circular supply chains.

The post Identiv : Strengthening Cold Chain Accountability for GLP-1 Therapies appeared first on Healthcare Outlook.

TECH-ENABLED SUCCESS

In the UK right now, nearly 650,000 people are currently out of work due to musculoskeletal (MSK) problems.

That’s 650,000 people who can’t do the jobs they want to do, support their families, or live the lives they planned. This isn’t just a healthcare crisis, but an economic one.

The NHS is tackling this with a preventative approach to care, starting with the rollout of the WorkWell scheme and, more recently, a tech-enabled programme designed to help patients manage their conditions remotely and get back to work sooner. 

The success of the programme demonstrates the importance of preventative care, with a 20 percent reduction in 18-week-plus community MSK waiting lists across the UK.

However, with an existing waiting list of 350,000, the NHS can’t address this crisis alone. To get Britain back to work, the government must also look to the private MSK sector – which already delivers a third of all physiotherapy – to accelerate efforts with tech-led interventions.

THE AGILITY ADVANTAGE

Technology plays a core role in scaling different types of MSK support across the country. Whether it’s connecting a patient to the right expert for treatment or facilitating remote care, digital solutions are needed to streamline patient pathways so a patient waiting three weeks can be seen in one.

When it comes to trialing and scaling solutions, the private sector has the advantage of being able to move faster than the public sector.

Private clinics can adopt new technology without the lengthy procurement cycles the NHS has to work through. That means they can integrate AI-driven triaging and automated workflows in weeks rather than years.

By working in tandem with the NHS, private providers can act as a fast-moving extension of national efforts to get people back to work.

Many clinics are adopting clinic management platforms to manage appointments, connect patients with the right specialists for their needs, and automate patient communications.

These features cut down on admin, free up clinicians’ time, and mean more patients can be seen – without increasing headcount costs. These are essential capabilities to help work through long NHS waiting lists.

PERSONALISED CARE

As well as helping practitioners to treat more patients, digital solutions can help MSK clinics provide more tailored care. Modern integrated platforms make specialist care more scalable – particularly with hybrid care models that combine remote and in-person treatment options.

For example, for a patient with limited mobility who would prefer to receive treatment at home, an integrated platform can give them greater control over their treatment plan with personalised exercise data and remote monitoring.

That means treatment that fits around the patient’s lifestyle, which contributes to faster progress and a return to work.

Beyond hybrid care models, digital tools also help clinics personalise care based on preferences such as language, gender and practitioner specialism, ensuring that patients receive the best care for their needs.

SCALING IMPACT

By adopting the right tools to manage admin, clinics can focus more on patient care and scale their operations to help more people.

A great example of this is a Belfast-based MSK clinic we work with that achieved a 100 percent year-on-year increase in new patient bookings by adopting automation features.

The clinic implemented TM3’s online booking portal, empowering patients to manage and change appointments themselves. That gave significant time back to clinics, which was reinvested into reaching new patients.

Paired with marketing integrations, it enabled the clinic to significantly grow its operations and see more patients.

This example is just one clinic. Scale that across every private MSK clinic in the country, and the numbers add up quickly.

GIVING MORE PEOPLE THE CHANCE TO GET BACK TO WORK

Solving the MSK crisis is essential to the UK’s general and economic health, and addressing workforce inactivity requires making use of every available resource.

Beyond NHS initiatives, the private sector has proven, practical technology that’s already helping MSK practitioners treat more patients faster and more effectively.

By empowering private clinics with technology, we can accelerate the successes we’ve already seen from government-led policies, help alleviate the strain on NHS waiting lists and make staying and returning to work a reality for hundreds of thousands of people.

The question for every private MSK clinic isn’t whether to adopt digital tools – it’s how quickly they can.

The post The Digital Backbone : Why private MSK clinics are the secret weapon in Britain’s ‘Back to Work’ strategy appeared first on Healthcare Outlook.

Building on Packaging and Circular Economy Progress

The strategy centers on integrating sustainability into core operations, with an emphasis on value creation for the business, communities, and the environment.

The new roadmap builds on progress achieved under the company’s 2025 strategy, particularly in packaging innovation.

Since introducing a recyclable toothpaste tube in 2019, Colgate-Palmolive has transitioned approximately 97% of toothpaste SKUs in North America and 98% globally to recyclable formats. These tubes are now sold in more than 70 countries worldwide.

Across its broader portfolio, around 96% of packaging is currently designed for recycling, with a target of reaching 100% by 2030.

Embedding Sustainability into Business Strategy

Colgate-Palmolive emphasized that sustainability is being integrated directly into its business model to drive innovation and long-term value.

Ann Tracy, Chief Sustainability Officer at Colgate-Palmolive, said:

“Our 2030 Strategy targets the areas where we can make the greatest difference, fostering growth for our business and our communities.”

“This work involves Colgate-Palmolive People around the world and supports our purpose to reimagine a healthier future for all.”

Expanding Social Impact Through Global Health Programs

Colgate-Palmolive continues to scale its social impact initiatives as part of its sustainability agenda.

The Colgate Bright Smiles, Bright Futures program has reached approximately 2 billion children and their families in over 100 countries since 1991, providing oral health education and support. The company aims to expand this to 2.7 billion people by 2030.

In parallel, its Hill’s Food, Shelter & Love program in the United States has delivered over $300 million in pet food donations, supporting more than 1,000 shelters and helping over 16 million pets find homes since 2002.

Advancing Renewable Energy and Climate Targets

Colgate-Palmolive is also progressing its climate transition plan. As of the end of 2025, approximately 83% of its global electricity use comes from renewable energy sources, with a target of reaching 100% by 2030.

These efforts form part of a broader push to build a climate-resilient value chain and improve operational sustainability.

Three Strategic Pillars Drive 2030 Roadmap

The company’s 2030 strategy is structured around three core ambitions:

•             Driving Social Impact through inclusion, wellbeing, and healthier habits

•             Helping Millions of Homes by delivering sustainable product innovation and improving lives for people and pets

•             Preserving the Environment by addressing plastic waste, climate resilience, water security, operational efficiency, and biodiversity

Together, these pillars are designed to align sustainability goals with business performance.

Committing to Impact

“I continue to be inspired and optimistic about our future, especially as CP People around the world are committing to impact and innovating to support a healthier planet,” adds Ann Tracy.

“As we look toward 2030, we will focus on how our actions drive value creation, fostering long-term growth and resilience for people, pets and the planet – we call this our win-win-win principle. We Make more Smiles when we create this positive fly-wheel.”

Focus on Value Creation and Operational Resilience

The company highlighted that its approach prioritizes high-impact initiatives designed to deliver benefits across consumers, the business, and the planet.

By embedding sustainability into operations, Colgate-Palmolive aims to strengthen resilience, support innovation, and meet evolving expectations from stakeholders, including customers, employees, partners, and investors.

Next Steps and 2030 Outlook

The 2030 Sustainability & Social Impact Strategy is fully integrated into the company’s broader strategic plan.

Colgate-Palmolive plans to report progress and introduce additional 2030 targets in its upcoming Sustainability and Social Impact Report later this year.

The post Colgate-Palmolive Unveils 2030 Sustainability Strategy to Drive Growth and Impact appeared first on Healthcare Outlook.

AT THE FOREFRONT OF AI HEALTH TRANSFORMATION  

Novo Nordisk has announced a strategic partnership with OpenAI, positioning the company at the forefront of artificial intelligence (AI) transformation in healthcare and accelerating the delivery of new treatments to patients. 

The collaboration will see advanced AI capabilities applied to analyse complex datasets, identify promising drug candidates, and reduce the time taken to progress from research to patient. The partnership has been established with strict data protection, governance, and human oversight to ensure ethical and compliant use. 

“This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare. There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,” says Mazier Mike Doustdar, President and CEO of Novo Nordisk.   

“Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever. This means discovering new therapies and bringing them to market faster than ever before.” 

FORGING BUSINESS DEVELOPMENT  

OpenAI will also support Novo Nordisk in upskilling its global workforce and strengthening AI literacy. In addition, the partnership will apply AI capabilities to enhance efficiency across manufacturing, supply chain and distribution, and corporate operations. Pilot programmes will also be launched across R&D, manufacturing, and commercial operations, with full integration targeted by the end of 2026. 

“AI is reshaping industries, and in life sciences, it can help people live better, longer lives,” adds Sam Altman, CEO of OpenAI.  

“This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.” 

The agreement builds on Novo Nordisk’s existing AI initiatives, including collaborations with technology partners and research organisations to develop best-in-class capabilities. 

ABOUT NOVO NORDISK  

Headquartered in Denmark, Novo Nordisk is a leading global healthcare organisation. Since its inception in 1923, the company has delivered on its purpose to drive change, defeat serious chronic illness, and build upon its heritage in diabetes. 

Novo Nordisk achieves this by pioneering scientific breakthroughs, expanding access to cutting-edge medicines, and working to prevent and ultimately cure disease across its global footprint of 170+ countries.  

The post Novo Nordisk and OpenAI Partnership Transforms Medicine Discovery appeared first on Healthcare Outlook.

Agentic AI designed to simplify drug discovery workflows

The platform is aimed at helping scientists design and test drug candidates faster during the early stages of development, with AWS positioning the application as a way to reduce complexity in AI-powered pharmaceutical research and make advanced computational tools more accessible to scientists without coding expertise.

According to AWS, Amazon Bio Discovery provides researchers with direct access to a catalog of specialised biological foundation models (bioFMs) trained on biological datasets to generate and evaluate potential drug candidates.

A core feature of the platform is an AI agent that enables scientists to use natural language to guide research workflows, helping users select the right AI models, optimise inputs and evaluate candidates for experimentation.

AWS said the application also allows scientists to train models using prior experimental data from their own organisations, improving prediction accuracy and reducing the number of experimental iterations needed.

“AI agents make powerful scientific capabilities accessible to all drug researchers, not just those with computational expertise,” said Rajiv Chopra, vice president of AWS Healthcare AI and Life Sciences.

“These AI systems can help scientists design drug molecules, coordinate testing, learn from results, and get smarter with each experiment. This combination of cutting-edge AI and the robust, secure infrastructure AWS has built for regulated industries allows scientists to accelerate antibody discovery in ways that weren’t possible before.”

Integrated lab testing closes the experimentation loop

Amazon Bio Discovery includes integrated laboratory partners that allow researchers to send top-performing antibody candidates directly for synthesis and testing.

Partners currently include Twist Bioscience and Ginkgo Bioworks, with A-Alpha Bio expected to join soon.

AWS said test results are then routed back into the platform to create a “lab-in-the-loop experimentation cycle,” allowing each experiment to improve subsequent rounds of design.

The company said the platform is intended to replace fragmented workflows where researchers currently manage disconnected systems, multiple lab partners and manual coordination.

Memorial Sloan Kettering used platform to accelerate antibody design

Memorial Sloan Kettering Cancer Center (MSK) used Amazon Bio Discovery to accelerate antibody design for potential paediatric cancer therapies.

Working with MSK, AWS said the platform designed nearly 300,000 novel antibody molecules, with the 100,000 top candidates sent to Twist Bioscience for testing.

According to AWS, a process that can take up to a year using traditional design methods was reduced to weeks from candidate design through lab testing.

“We’re glad to be able to join forces with Amazon Bio Discovery to develop the next generation of antibodies that will potentially speed up the process to help patients worldwide,” said Nai-Kong Cheung M.D., Ph.D., Enid A. Haupt Chair in Pediatric Oncology at Memorial Sloan Kettering Cancer Center.

“As researchers, we spent 20 years just to prove that the first generation of antibody worked, and then we spent another 13 years getting it into the human form before getting FDA approval. This path has been very inefficient. Patients come here with a clock. We need results sooner.”

Built for enterprise life sciences adoption

AWS said Amazon Bio Discovery is built on infrastructure already used by the pharmaceutical industry, noting that 19 of the top 20 global pharmaceutical companies use AWS for research workloads.

The company said the platform offers enterprise-grade scale, performance, privacy and security, with complete data isolation and customer ownership over proprietary data and intellectual property.

Early adopters include Bayer, the Broad Institute, Fred Hutch Cancer Center and Voyager Therapeutics.

The post AWS Launches Amazon Bio Discovery to Accelerate AI-Driven Drug Research appeared first on Healthcare Outlook.

CONSUMER PRODUCTS SHAPED BY ECODESIGN  

Sustainability is increasingly shaping the consumer health market. Products marketed as sustainable recorded an eight percent increase in value between 2020 and 2023, outperforming the broader category, according to Euromonitor International. 

At the same time, global demand for renewable and sustainable energy sources and materials continues to grow, supported by the expansion of bio-based products. 

This interest is also evident in personal health, where three in four consumers report strong interest in bio-based personal care products. 

For Philips, this shift correlates with its position as an established sustainability leader. For instance, in 2020, the company reached its target of carbon neutrality in its operations and began sourcing 100 percent of its electricity from renewable sources.  

Philip’s fundamental principle of improving people’s health and well-being through meaningful innovation extends across the entire value chain, from the supply chain to the materials and packaging used.  

The company develops new products and services in line with its EcoDesign principles, which guide efforts to improve energy efficiency, reduce reliance on virgin materials, increase recycled content, and phase out hazardous substances.  

Teams also prioritise circular design, making products easier to repair and recycle, whilst simplifying packaging so it can be reused or more efficiently processed at end of life. 

Driven by growing consumer preference for more eco-friendly products, alongside its commitment to more sustainable operations, Philips Personal Health is investing in the use of bio-based materials, whilst continuing to support healthier, longer lives.  

The full portfolio of Philips Sonicare toothbrush heads is now made from 70 percent bio-based plastic, and the company has expanded its use of paper-based packaging. These developments represent two examples of improvements across product design and packaging. 

FORGING A BETTER FUTURE FOR BABY PRODUCTS  

Today, more parents are being influenced to purchase sustainably sourced products. With eco-friendly materials emerging as a key area of innovation, the brand has taken significant steps to capitalise on this bio-based opportunity. 

One example is the upcoming launch of Philips Avent’s Ultra Pacifiers. Trusted by parents worldwide, the new pacifiers are made from 80 percent plant-based material. This is derived entirely from vegetable oil, contains no animal fats, and does not compete with the food chain. As a renewable resource, it also generates lower carbon dioxide emissions. 

While research shows that bio-based materials and processes can deliver environmental, social, and economic benefits, Philips Avent needed to ensure the pacifiers met the highest standards of sustainability, safety, and comfort for babies, explains Mirko Cartei, R&D Leader, Mother & Child Care: 

“As part of our commitment to making all new and redesigned Philips Avent products more sustainable, the biggest challenge was ensuring we selected the right material and its traceable supply chain.  

“This process involved lengthy discussions with different suppliers, followed by thorough testing to ensure the materials met health and safety standards. We also had to review and study suppliers’ sustainability reports (Life Cycle Analysis) and coordinate the certification of the material supply chain traceability.  

“This process involved us obtaining a lot of data that we then had to examine and process,” adds Mirko. 

RECONDITIONING AND REFURBISHING 

Growing demand for more sustainable and affordable options is also shaping consumer interest in refurbished goods. Surveys indicate that more than 70 percent of millennials and Gen Z consumers are open to purchasing refurbished electronics, in particular.  

Through its Refurb Editions programme, Philips restores a selection of Personal Health products, including Philips Lumea IPL hair removal devices, Sonicare toothbrushes, and selected shavers. Many of these products were previously sold online and returned within 30 days.  

Philips replaces hygiene-related components, such as shaver blades, and thoroughly cleans each item. Products are then tested to ensure they meet strict quality standards before being repackaged in original or recycled materials and sold with a two-year warranty.  

In 2024, more than 30,000 refurbished Philips-branded products were resold, with an estimated nine kilotonnes of products and packaging recycled in the EU alone. 

PILOTING 3D PRINTING PARTS FOR DIY CONSUMERS  

With 77 percent of Europeans indicating they would prefer to repair a product rather than replace it, Philips Personal Health has partnered with Prusa Research, a leader in 3D printing, to launch a pilot programme in Czechia called Fixables.  

The initiative provides free access to 3D-printable files for selected Philips accessory parts. Using these open-access files, consumers can repair components that are lost, worn, or out of warranty, rather than replacing the entire product.  

The pilot aims to strengthen the brand’s circular model, enabling consumers to extend product lifecycles without compromising on quality. 

FROM PLASTIC TO PAPER  

Consumers increasingly expect brands to innovate across both products and packaging to reduce environmental impact.  

This includes adopting more sustainable materials and developing solutions that minimise waste. Philips Personal Health continues to expand its use of more environmentally driven packaging across its portfolio.  

This commitment is evident in several areas: all Sonicare brush heads are now packaged in recyclable materials, whilst products such as the Philips OneBlade and Philips i9000 shavers feature paper-based packaging. In addition, the newly redesigned Ultra Pacifiers are sold in sustainable or recyclable packaging. 

DEDICATED TO PLANET AND PEOPLE 

Each step towards a healthier planet matters, and consumers expect brands to clearly demonstrate both their commitment to sustainability and the progress they are making.  

This shift towards more sustainable materials and design approaches reflects a broader evolution that will continue to reshape how products are made, used, and reused in the years ahead. 

Philips is progressing on this journey alongside consumers. Having achieved its goal of becoming 100 percent carbon neutral in its own operations in 2020, the company is now advancing its environmental ambitions for 2030.  

These include reducing the use of virgin non-renewable materials and increasing the availability of materials for reuse. By rethinking product design and packaging, and extending product lifecycles through refurbishment, Philips is making sustainability more tangible for consumers. 

The post Philips Drives a Circular Economy Through Sustainable Design appeared first on Healthcare Outlook.